MicuRx Approved for China Launch of Next-Gen Antibiotic

MicuRx Pharma was approved for  China commercialization of contezolid, its next-gen oxazolidinone antibiotic, to treat complicated skin and soft tissue infection. MicuRx has completed nine contezolid clinical trials both in and outside of  China showing efficacy in treating infections caused by multi-drug resistant gram-positive bacteria, while reducing the myelosuppression side effects or inducing drug resistance. Initially, MicuRx will launch contezolid in  China while it conducts additional trials in the US . It will be the first MicuRx product to be commercialized. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.